Abstract
Prostate cancer is one of the most common health threats for men in the developed world. With the advent of prostate cancer screening using serum prostate-specific antigen (PSA) tests, prostate cancer mortality has declined at the expense of substantial disease overtreatment. Active surveillance of low-risk prostate cancer may obviate the need for immediate treatment for many men. Surgery and radiation therapy remain mainstay approaches to localized prostate cancer; systemic treatments targeting androgen signaling are used for more advanced disease. Taxane chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors are emerging as treatment options for castration-resistant prostate cancer (CRPC).
Original language | English (US) |
---|---|
Title of host publication | Abeloff’s Clinical Oncology |
Publisher | Elsevier |
Pages | 1401-1432.e7 |
ISBN (Electronic) | 9780323476744 |
DOIs | |
State | Published - Jan 1 2019 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2017 Elsevier Inc.
Keywords
- Active surveillance
- Androgen deprivation therapy
- Antiandrogen
- Intensity-modulated radiation therapy
- Poly (ADP-ribose) polymerase (PARP) inhibitors
- Proliferative inflammatory atrophy
- Prostate cancer
- Prostate-specific antigen
- Radical prostatectomy
- Taxane chemotherapy